Evaluation of the Effect of Vitamin E (alpha-tocopherol) Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis

What this Trial Is About

This research aims to determine whether supplementation with vitamin E (alpha-tocopherol) reduces inflammation and clinical activity in patients with rheumatoid arthritis (RA). RA is a common autoimmune disease causing chronic joint inflammation and potential joint damage, which leads to disability and affects quality of life. The study focuses on patients with early RA who have low vitamin E intake and are already receiving standard RA treatments. Participants will be randomly assigned to one of two groups: one group will receive conventional synthetic disease-modifying antirheumatic drugs (FARMEs) plus 800 mg per day of vitamin E, while the other group will receive the same FARMEs plus a 200 mg per day magnesium oxide placebo. The supplementation lasts for one month, with participants taking two capsules daily, one in the morning and one in the afternoon. During the study, participants will attend clinic visits at the start and end of the supplementation period for assessments including clinical activity, blood tests measuring vitamin E levels, inflammatory markers, autoantibodies, and antioxidant capacity. They will keep a diary to track symptoms and supplement intake. Researchers will evaluate changes in vitamin E levels, clinical disease activity (DAS-28), pro-inflammatory cytokines, acute phase reactants, and autoantibodies to understand the impact of vitamin E supplementation on RA.

"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"